Robert Pascuzzi is a Neurology physician affiliated with Indiana University Health. OpenAlex indexes 166 publications with 7,950 citations (h-index 40); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1050 Wishard Blvd
Indianapolis, IN 462022872
Telephone
317-274-8800Provider last certified this registry record 15 Mar 2025.
Clinical trials
- CC100: Safety and Tolerability of Single Doses
Sponsor: Chemigen, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year20253 payments
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- ARGENX US, INC.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
74.7%Benzodiazepine12.2%Clonazepam47%Diazepam31%Alprazolam15%Lorazepam7%Part D<11 patientsOther antiepileptics11.2%Levetiracetam52%Topiramate41%Lacosamide6%Part D<11 patients+ 23 more classes in this area
Respiratory
7.4%Opioid Agonist6.3%Hydrocodone-Acetaminophen100%Part D≥18 patientsOther antihistamines for systemic use0.7%Cyproheptadine Hcl100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
6.7%gamma-Aminobutyric Acid-ergic Agonist3%Baclofen100%Part D≥16 patientsMuscle Relaxant2.2%Cyclobenzaprine Hcl51%Carisoprodol27%Methocarbamol22%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study
Proceedings of the National Academy of Sciences
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”